Mendota Financial Group LLC Sells 393 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mendota Financial Group LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 15.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,224 shares of the biopharmaceutical company’s stock after selling 393 shares during the period. Mendota Financial Group LLC’s holdings in Halozyme Therapeutics were worth $106,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $49,000. Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth approximately $57,000. FSC Wealth Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $65,000. Finally, Park Place Capital Corp boosted its holdings in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,209 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HALO. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $54.14 on Tuesday. The company has a market capitalization of $6.89 billion, a PE ratio of 17.93, a P/E/G ratio of 0.44 and a beta of 1.24. The company has a 50-day simple moving average of $50.05 and a two-hundred day simple moving average of $54.05. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.